HC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $25 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Patrick Trucchio reiterates a Buy rating on Milestone Pharmaceuticals (NASDAQ:MIST) and maintains a $25 price target.
May 23, 2023 | 1:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Patrick Trucchio reiterates a Buy rating on Milestone Pharmaceuticals and maintains a $25 price target.
The Buy rating and maintained $25 price target by HC Wainwright & Co. analyst Patrick Trucchio indicates a positive outlook for Milestone Pharmaceuticals. This news is likely to have a positive impact on the stock price in the short term as it reaffirms the analyst's confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100